Monte Rosa Therapeutics, Inc. (GLUE) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 170.69M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 20.59M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -181.85M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $170.69M | (m) | $20.59M | $-181.85M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $153.38M | (m) | $19.52M | $-148.28M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $141.50M | (m) | $18.86M | $-54.21M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $138.39M | (m) | $19.02M | $8.51M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $129.32M | (m) | $18.94M | $14.96M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $126.73M | (m) | $18.55M | $-2.13M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $121.56M | (m) | $18.13M | $-81.11M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $109.83M | (m) | $17.73M | $-128.98M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $110.52M | (m) | $17.92M | $-139.42M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $111.54M | (m) | $17.57M | $-144.00M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $111.27M | (m) | $16.67M | $-143.31M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $109.00M | (m) | $15.92M | $-140.94M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $102.04M | (m) | $14.67M | $-132.33M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $93.90M | (m) | $13.39M | $-122.34M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $85.06M | (m) | $11.66M | $-112.38M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $78.32M | (m) | $10.19M | $-103.28M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $72.10M | (m) | $9.05M | $-94.79M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $65.80M | (m) | $7.20M | $-85.68M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $57.16M | (m) | $5.20M | $-72.88M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $24.00M | (m) | $354.00K | $-28.01M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |